Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2021 May 11;5(9):2375-2384.
doi: 10.1182/bloodadvances.2021004467.

Optimal timing and criteria of interim PET in DLBCL: a comparative study of 1692 patients

J J Eertink  1 , C N Burggraaff  1 , M W Heymans  2 , U Dührsen  3 , A Hüttmann  3 , C Schmitz  3 , S Müller  4 , P J Lugtenburg  5 , S F Barrington  6 , N G Mikhaeel  7 , R Carr  8 , S Czibor  9 , T Györke  9 , L Ceriani  10   11 , E Zucca  11   12 , M Hutchings  13 , L Kostakoglu  14 , A Loft  15 , S Fanti  16 , S E Wiegers  1 , S Pieplenbosch  1 , R Boellaard  17 , O S Hoekstra  17 , J M Zijlstra  1 , H C W de Vet  2
Affiliations

Optimal timing and criteria of interim PET in DLBCL: a comparative study of 1692 patients

J J Eertink et al. Blood Adv. .

Abstract

Interim 18F-fluorodeoxyglucose positron emission tomography (Interim-18F-FDG-PET, hereafter I-PET) has the potential to guide treatment of patients with diffuse large B-cell lymphoma (DLBCL) if the prognostic value is known. The aim of this study was to determine the optimal timing and response criteria for evaluating prognosis with I-PET in DLBCL. Individual patient data from 1692 patients with de novo DLBCL were combined and scans were harmonized. I-PET was performed at various time points during treatment with rituximab plus cyclophosphamide, doxorubicin, vincristine, and prednisone (R-CHOP) therapy. Scans were interpreted using the Deauville score (DS) and change in maximum standardized uptake value (ΔSUVmax). Multilevel Cox proportional hazards models corrected for International Prognostic Index (IPI) score were used to study the effects of timing and response criteria on 2-year progression-free survival (PFS). I-PET after 2 cycles (I-PET2) and I-PET4 significantly discriminated good responders from poor responders, with the highest hazard ratios (HRs) for I-PET4. Multivariable HRs for a PET-positive result at I-PET2 and I-PET4 were 1.71 and 2.95 using DS4-5, 4.91 and 6.20 using DS5, and 2.93 and 4.65 using ΔSUVmax, respectively. ΔSUVmax identified a larger proportion of poor responders than DS5 did. For all criteria, the negative predictive value was >80%, and positive predictive values ranged from 30% to 70% at I-PET2 and I-PET4. Unlike I-PET1, I-PET3 discriminated good responders from poor responders using DS4-5 and DS5 thresholds (HRs, 2.94 and 4.67, respectively). I-PET2 and I-PET4 predict good response equally during R-CHOP therapy in DLBCL. Optimal timing and response criteria depend on the clinical context. Good response at I-PET2 is suggested for de-escalation trials, and poor response using ΔSUVmax at I-PET4 is suggested for randomized trials that are evaluating new therapies.

PubMed Disclaimer

Conflict of interest statement

Conflict-of-interest disclosure: U.D. received research funding from Amgen and Roche and honoraria for participating in advisory boards from Amgen and Roche. P.J.L. received research funding from Takeda, Servier, and Roche and honoraria for participating in advisory boards from Takeda, Servier, Roche, Genmab, Celgene, Regeneron, and Incyte. S.F.B. is on the speakers bureau for Takeda and Hoffman la Roche and received departmental funding from Bristol Myers Squibb, Pfizer, and Amgen. J.M.Z. received research funding from Roche and received honoraria for participating in advisory boards from Takeda, Gilead, and Roche. The remaining authors declare no competing financial interests.

Figures

None
Graphical abstract
Figure 1.
Figure 1.
CONSORT diagram of patient inclusion.
Figure 2.
Figure 2.
PPS from day of baseline scan for individual studies included in our analysis. (A) Kaplan-Meier survival curve for 5-year PFS for all studies. (B) Uncorrected Cox regression 2-year PFS for all studies. (C) Cox regression corrected for IPI score for 2-year PFS for all individual studies.
Figure 3.
Figure 3.
Two-year PFS Cox regression stratified for DS4-5 I-PET–positive patients and timing. Corrected for low-risk (A), low-intermediate risk (B), high-intermediate risk (C), and high-risk (D) IPI groups.
Figure 4.
Figure 4.
Two-year PFS Cox regression stratified for DS5 I-PET–positive patients and timing. Corrected for low-risk (A), low-intermediate risk (B), high-intermediate risk (C), and high-risk (D) IPI groups. For all risk groups, I-PET2–positive and I-PET3–positive regression curves are superimposed.
Figure 5.
Figure 5.
Two-year PFS Cox regression stratified for ΔSUVmax I-PET–positive patients and timing. Corrected for low-risk (A), low-intermediate risk (B), high-intermediate risk (C), and high-risk (D) IPI groups.
See this image and copyright information in PMC

References

    1. Gisselbrecht C, Glass B, Mounier N, et al. . Salvage regimens with autologous transplantation for relapsed large B-cell lymphoma in the rituximab era. J Clin Oncol. 2010;28(27):4184-4190. - PMC - PubMed
    1. Crump M, Neelapu SS, Farooq U, et al. . Outcomes in refractory diffuse large B-cell lymphoma: results from the international SCHOLAR-1 study. Blood. 2017;130(16):1800-1808. - PMC - PubMed
    1. Burggraaff CN, de Jong A, Hoekstra OS, et al. . Predictive value of interim positron emission tomography in diffuse large B-cell lymphoma: a systematic review and meta-analysis. Eur J Nucl Med Mol Imaging. 2019;46(1):65-79. - PMC - PubMed
    1. International Non-Hodgkin’s Lymphoma Prognostic Factors Project . A predictive model for aggressive non-Hodgkin’s lymphoma. N Engl J Med. 1993;329(14):987-994. - PubMed
    1. Cheson BD, Fisher RI, Barrington SF, et al. ; United Kingdom National Cancer Research Institute . Recommendations for initial evaluation, staging, and response assessment of Hodgkin and non-Hodgkin lymphoma: the Lugano classification. J Clin Oncol. 2014;32(27):3059-3068. - PMC - PubMed

Publication types

MeSH terms